Treatment of methicillin-resistant Staphylococcus aureus in Latin America

Brazilian Journal of Infectious Diseases

Volumn 14, Issue SUPPL. 2, 2010, Pages

  Luna, Carlos M ^a   Rodríguez Noriega, Eduardo ^b   Bavestrello, Luis ^c   Gotuzzo, Eduardo ^d  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^c Unidad de Cuidados Intensivos   (Chile)

^d UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

Antibiotic therapy; Latin america; Mrsa; Treatment

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; POLYPEPTIDE ANTIBIOTIC AGENT; PSEUDOMONIC ACID; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANAPHYLAXIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ARTHRITIS; BONE INFECTION; CATHETER INFECTION; CHRONIC OSTEOMYELITIS; COMBINATION CHEMOTHERAPY; COMMUNICABLE DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG TREATMENT FAILURE; HEMODIALYSIS; HOSPITAL INFECTION; HUMAN; INFECTION RISK; INJECTION SITE REACTION; JOINT PROSTHESIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PRACTICE GUIDELINE; PROSTHESIS INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; SOUTH AND CENTRAL AMERICA; SURGICAL INFECTION; THERAPY DELAY; TREATMENT DURATION;

EID: 78650931624     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1413-86702010000800007     Document Type: Article

References (78)

1. American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital- acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171(4):388-416.
2. Luna CM, Monteverde A, Rodriguez A et al. Clinical guidelines for the treatment of nosocomial pneumonia in Latin America: an interdisciplinary consensus document. Recommendations of the Latin American Thoracic Society. Arch Bronconeumol. 2005; 41(8):439-56.
3. Song JH. Treatment recommendations of hospital-acquired pneumonia in Asian countries: first consensus report by the Asian HAP Working Group. Am J Infect Control. 2008; 36(4 Suppl):S83-92.
4. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44(Suppl 2):S27-72.
5. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005; 41(10):1373-406.
6. Mermel LA, Farr BM, Sherertz RJ et al. Guidelines for the management of intravascular catheter-related infections. J Intraven Nurs. 2001; 24(3):180-205.
7. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006; 43(4):518-24.
8. Gemmell CG, Edwards DI, Fraise AP et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother. 2006; 57(4):589-608.
9. Nathwani D, Morgan M, Masterton RG et al. Guidelines for UK practice for the diagnosis and management of methicillin- resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother. 2008; 61(5):976-94.
10. Siegel JD, Rhinehart E, Jackson M, Chiarello L. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007; 35(10 Suppl 2):S165-93.
11. Deresinski S. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis. 2007; 45(Suppl 3):S177-83.
12. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999; 115(2):462-74.
13. Baudel JL, Tankovic J, Carrat F et al. Does nonadherence to local recommendations for empirical antibiotic therapy on admission to the intensive care unit have an impact on inhospital mortality? Ther Clin Risk Manag. 2009; 5(3):491-8.
14. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000; 31(Suppl 4):S131-8.
15. Farrington M. Infection control education: how to make an impact- tools for the job. J Hosp Infect. 2007; 65(Suppl 2):128-32.
16. Sader HS, Moet GJ, Jones RN. Antimicrobial resistance among Gram-positive bacteria isolated in Latin American hospitals. J Chemother. 2009; 21(6):611-20.
17. Robicsek A, Beaumont JL, Thomson RB, Jr. et al. Topical therapy for methicillin-resistant Staphylococcus aureus colonization: impact on infection risk. Infect Control Hosp Epidemiol. 2009; 30(7):623-32.
18. Shittu AO, Udo EE, Lin J. Phenotypic and molecular characterization of Staphylococcus aureus isolates expressing low- and high-level mupirocin resistance in Nigeria and South Africa. BMC Infect Dis. 2009; 9:10.
19. Hyun DY, Mason EO, Forbes A, Kaplan SL. Trimethoprim-sulfamethoxazole or clindamycin for treatment of communityacquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J. 2009; 28(1):57-9.
20. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006; 355(7):666-74.
21. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother. 2007; 51(2):423-8.
22. Pappas G, Athanasoulia AP, Matthaiou DK, Falagas ME. Trimethoprim- sulfamethoxazole for methicillin-resistant Staphylococcus aureus: a forgotten alternative? J Chemother. 2009; 21(2):115-26.
23. Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007; 51(9):3298-303.
24. Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev. 2010; 23(1):14-34.
25. Perlroth J, Kuo M, Tan J et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med. 2008; 168(8):805-19.
26. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988; 158(1):23-8.
27. Martinez-Aguilar G, Hammerman WA, Mason EO, Jr., Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillinsusceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003; 22(7):593-8.
28. Gemmell CG. Antibiotics and the expression of staphylococcal virulence. J Antimicrob Chemother. 1995; 36(2):283-91.
29. Lewis JS, 2nd, Jorgensen JH. Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis. 2005; 40(2):280-5.
30. Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulasenegative staphylococci. J Clin Microbiol. 2003; 41(10):4740-4.
31. Weigelt J, Itani K, Stevens D et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005; 49(6):2260-6.
32. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003; 138(2):135-42.
33. Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin. 2010; 26(3):571-88.
34. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/ static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2006; 42(Suppl 1):S13-24.
35. Hiramatsu K, Hanaki H, Ino T et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997; 40(1):135-6.
36. Smith TL, Pearson ML, Wilcox KR et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999; 340(7):493-501.
37. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillinresistant Staphylococcus aureus infection. N Engl J Med. 1999; 340(7):517-23.
38. Tenover FC, Weigel LM, Appelbaum PC et al. Vancomycinresistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother. 2004; 48(1):275-80.
39. Chang S, Sievert DM, Hageman JC et al. Infection with vancomycin- resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003; 348(14):1342-7.
40. Moise-Broder PA, Sakoulas G, Eliopoulos GM et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004; 38(12):1700-5.
41. Lodise TP, Miller CD, Graves J et al. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2008; 62(5):1138-41.
42. Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis. 2007; 45(Suppl 3):S191-5.
43. Rybak MJ, Lomaestro BM, Rotscahfer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009; 49(3):325-7.
44. Schaison G, Graninger W, Bouza E. Teicoplanin in the treatment of serious infection. J Chemother. 2000; 12(Suppl 5):26-33.
45. Polk RE. Anaphylactoid reactions to glycopeptide antibiotics. J Antimicrob Chemother. 1991; 27(Suppl B):17-29.
46. Babinchak T, Ellis-Grosse E, Dartois N et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis. 2005; 41(Suppl 5):S354-67.
47. McAleese F, Murphy E, Babinchak T et al. Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates. Antimicrob Agents Chemother. 2005; 49(11):4521-9.
48. Rodvold KA, Gotfried MH, Cwik M et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006; 58(6):1221-9.
49. Boucher HW, Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis. 2007; 45(5):601-8.
50. Arbeit RD, Maki D, Tally FP et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skinstructure infections. Clin Infect Dis. 2004; 38(12):1673-81.
51. Silverman JA, Mortin LI, Vanpraagh AD et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005; 191(12):2149-52.
52. Torralba MD, Frey SE, Lagging LM. Treatment of methicillinresistant Staphylococcus aureus infection with quinupristin/ dalfopristin. Clin Infect Dis. 1995; 21(2):460-1.
53. Drew RH, Perfect JR, Srinath L et al. Treatment of methicillinresistant Staphylococcus aureus infections with quinupristindalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother. 2000; 46(5):775-84.
54. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis. 2003; 36(4):473-81.
55. Chambers HF, Hegde SS. Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin? Expert Rev Anti Infect Ther. 2007; 5(3):333-5.
56. Sopena N, Sabria M. Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest. 2005; 127(1):213-9.
57. Rotstein C, Evans G, Born A et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol. 2008; 19(1):19-53.
58. Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents. 2000; 16(Suppl 1):S31-4.
59. Chastre J, Wolff M, Fagon JY et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003; 290(19):2588-98.
60. Corey GR. Staphylococcus aureus bloodstream infections: definitions and treatment. Clin Infect Dis. 2009; 48(Suppl 4):S254-9.
61. Anderson DJ, Kaye KS. Staphylococcal surgical site infections. Infect Dis Clin North Am. 2009; 23(1):53-72.
62. Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002; 34(11):1481-90.
63. Stamboulian D, Di Stefano C, Nacinovich F et al. Guidelines for the management of bone and joint infections due to methicillin resistant staphylococci. Medicina (B Aires). 2002; 62(Suppl 2):5-24.
64. Mandell LA. Antimicrobial resistance and treatment of community- acquired pneumonia. Clin Chest Med. 2005; 26(1):57-64.
65. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008; 46(Suppl 5):S344-9.
66. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis. 2001; 7(2):178-82.
67. Gorak EJ, Yamada SM, Brown JD. Community-acquired methicillin- resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis. 1999; 29(4):797-800.
68. Herold BC, Immergluck LC, Maranan MC et al. Communityacquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998; 279(8):593-8.
69. Miller LG, Perdreau-Remington F, Rieg G et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005; 352(14):1445-53.
70. Lipsky BA, Berendt AR, Deery HG et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004; 39(7):885-910.
71. Diep BA, Sensabaugh GF, Somboona NS et al. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton- Valentine leucocidin. J Clin Microbiol. 2004; 42(5):2080-4.
72. Vandenesch F, Naimi T, Enright MC et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis. 2003; 9(8):978-84.
73. Rodríguez-Noriega E, Seas C, Guzmán-Blanco M et al. Evolution of methicillin-resistant Staphylococcus aureus clones in Latin America. Int J Infect Dis. 2010; 14:e560-6.
74. Davis SL, Perri MB, Donabedian SM et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol. 2007; 45(6):1705-11.
75. Shorr AF. Epidemiology and economic impact of meticillinresistant Staphylococcus aureus: review and analysis of the literature. Pharmacoeconomics. 2007; 25(9):751-68.
76. Wong CH, Khin LW, Heng KS et al. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004; 32(7):1535-41.
77. Diep BA, Carleton HA, Chang RF et al. Roles of 34 virulence genes in the evolution of hospital- and community-associated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis. 2006; 193(11):1495-503.
78. Gordts B. Models for the organisation of hospital infection control and prevention programmes. Clin Microbiol Infect. 2005; 11(Suppl 1):19-23.